1,720,968 research outputs found
One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
Full text linkIntroduction: This study investigates the effects of dapagliflozin on the visceral adiposity index (VAI), lipid accumulation product (LAP), product of triglycerides and glucose (TyG) and triglycerides to HDL-cholesterol ratio (TG/HDL-C) in patients with type 2 diabetes mellitus (T2D).
Methods: In this real-life study, dapaglifozin was added to metformin alone (group 1, no. 42) or insulin plus metformin (group 2, no. 58) in 100 T2D patients.
Results: In group 1, after 6 months of dapaglifozin addition, a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), systolic blood pressure (SBP) (p = 0.009), diastolic blood pressure (DBP) (p = 0.012), mean fasting blood glucose (FBG), post-breakfast glucose (PBG), post-lunch glucose (PLG) and post-dinner glucose (PDG) (all p < 0.001), HbA1c (p < 0.001), VAI (p = 0.020), LAP (p = 0.028), Tyg (p < 0.001), TG/HDL-C (p = 0.020) and glutamate pyruvate transaminase (GPT) (p < 0.001) was observed compared to baseline. After 12 months a significant decrease in BMI (p < 0.001), WC (p = 0.006), SBP (p = 0.023), DBP (p = 0.005), mean FPG, PBG, PLG and PDG (all p < 0.001), HbA1c (p < 0.001), total cholesterol (p = 0.038), triglycerides (p = 0.026), VAI (p = 0.013), GPT (p < 0.001), LAP index (p = 0.024), Tyg index (p < 0.001) and TG/HDL-c ratio (p = 0.016) was observed compared to baseline. In group 2, after 6 months of dapaglifozin addition, a significant decrease in BMI (p < 0.001), WC (p < 0.001), SBP (p = 0.015), DBP (p = 0.007), mean FPG, PBG, PLG and PDG (all p < 0.001), HbA1c (p < 0.001), VAI (p = 0.040), LAP (p = 0.047), Tyg (p < 0.001), TG/HDL-C (p = 0.048) and GPT (p < 0.001) was observed compared to baseline. By contrast, after 12 months a significant decrease in BMI (p < 0.001), WC (p < 0.001), SBP (p = 0.001), DBP (p = 0.002), mean FPG, PBG, PLG and PDG (all p < 0.001), HbA1c (p < 0.001), GPT (p < 0.001) and Tyg index (p = 0.003) was observed compared to baseline.
Conclusions: Dapagliflozin treatment significantly reduced surrogate indexes of insulin resistance and adiposity in patients with T2D
Erratum to: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study (Diabetes Therapy, (2018), 9, 1, (363-371), 10.1007/s13300-017-0338-4)
No full textIn the original publication, the funding statement was incorrectly published and the Editorial Assistant information was missed in the published version. The correct funding statement and the Editorial Assistant statement should read as below. Funding. The study and article processing charges were funded by Novo Nordisk S.p.A. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and the accuracy of the data analysis. Editorial Assistance. Editorial assistance was provided by Paolo de Gennaro of Airon Communication. Support for this assistance was funded by Novo Nordisk S.p.A
Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
Full text linkDiversa efficacia clinica e biochimica della terapia con liraglutide in una popolazione di diabetici di tipo 2 in relazione ai valori basali di HbA1c
No full textBackground: I criteri AIFA di rimborsabilità dei farmaci ad azione incretino-mimetica limitano notevolmente l’utilizzo degli stessi ad un range molto ristretto di HbA1c alla prima prescrizione(7,5-8,5%), escludendone quindi dal loro utilizzo i pazienti con più severo scompenso glicometabolico.
Obiettivi: Valutare la diversa efficacia di liraglutide durante i primi 12 mesi di terapia in relazione ai valori di HbA1c di partenza.
Metodi: Sono stati retroattivamente valutati i dati clinici e metabolici di 62 pazienti diabetici di tipo 2 (38 M, 24 F, range età 29-74 aa, range durata di malattia 0-30 aa) trattati in un periodo antecedente l’entrata in vigore dei limiti di rimborsabilità AIFA, in terapia stabile per 12 mesi con liraglutide 1,2 mg/die, suddivisi in base all’HbA1c di partenza in gruppo A (n° 34 pz. con Hba1c ≤8,5%; media 7.3 ± 0.7%) e gruppo B (n° 28 pz. con Hba1c >8,5%; media 9.8 ± 1.2%). I due gruppi sono risultati appaiati per età, sesso, BMI, durata di malattia e terapia associata (n° 29 pz. in duplice con metformina, n° 33 pz. in triplice con metformina e sulfanilurea).
Risultati: In tutti i pazienti, indipendentemente dalla terapia associata, dopo 12 mesi si osserva una riduzione significativa di HbA1c (p<0,01), BMI (p<0,01), circonferenza vita (CV) (p<0,01), pressione sistolica (p<0,01) e diastolica (p<0,01) e il ∆-HbA1c a 12 mesi correla significativamente con il ∆-BMI (p=0.007) e ∆-CV (p=0.023). Il gruppo B mostra un ∆-BMI a 6 mesi (-1.8 ± 1.5 vs. -1 ± 1.4 Kg/m2; p=0.032) e un ∆-HbA1c sia a 6 (-2.9 ± 1.7 vs. -0.7 ± 0.7%; p<0.001) che a 12 mesi (-2.9 ± 1.7 vs. -0.5 ± 0.7%; p<0.001) significativamente superiore al gruppo A. Inoltre, un maggiore ∆-HbA1c sia a 6 (-2.3 ± 2 vs. -1.1 ± 1.1%; p=0.006) che a 12 mesi (-2.2 ± 2 vs. -1 ± 1.1%; p=0.010) si verifica nel gruppo in duplice terapia rispetto a quello in triplice.
Conclusioni: Liraglutide dimostra una migliore efficacia sia clinica che biochimica nei pazienti con scompenso glicometabolico più severo e verosimilmente in fase più precoce di malattia (duplice vs. triplice terapia)
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
- …
